Grove Biopharma Reports Preclinical Study in Nature Communications Demonstrating a Novel Approach to MYC and KRAS Degradation
Grove Biopharma, a private biotechnology company engineering protein-like polymers (PLPs) – a new class of multifunctional biologics designed to address the most challenging intracellular drug targets – today announced the publication of preclinical results demonstrating targeted degradation of two key oncogenic drivers enabled via its Bionic Biologics platform. The peer-reviewed study, titled “Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS,” was published today in Nature Communications. (DOI: 10.1038/s41467-026-68913-3).
Grove Biopharma to Participate in Materials Biology Symposium at ACS Fall 2025 Scientific Meeting
Grove Biopharma, a private biotechnology company pioneering its Bionic Biologics™ platform to develop therapies targeting previously intractable intracellular disease targets, announced today it will present an update at the annual American Chemical Society (ACS) Fall meeting being held August 17-21, 2025, in Washington D.C.
Grove Biopharma Closes $30 Million Series A Financing to Advance Bionic Biologics™, a New Therapeutic Modality
Grove Biopharma, a private biotechnology company pioneering its Bionic Biologics™ platform to develop therapies targeting previously intractable intracellular disease targets, today announced the close of a $30 million Series A financing. The round was led by DCVC Bio with participation from Eli Lilly and Company, InVivium Capital, Walder Ventures, Gradiant Corporation, Mansueto Investments, and others. They join existing seed supporters, including Portal Innovations, where Grove was incubated. Proceeds will be used to further advance Grove Biopharma’s proprietary platform and drive its lead oncology programs towards the clinic.
